These are the stocks posting the largest moves before the bell.Market Insiderread more
The Federal Reserve's expected interest rate cuts appears to have impacted J.P. Morgan's forecast for 2019 net interest income.Financeread more
J.P. Morgan chief Jamie Dimon praised the strength of the consumer after the largest U.S. bank posted strong second-quarter quarterly earnings release on Tuesday.Banksread more
Current and former Tesla employees working in the company's open-air "tent" factory say they felt pressure to take shortcuts to hit aggressive Model 3 production goals,...Technologyread more
KeyCorp said in an 8-K filing the fraud involves a "business customer" and was discovered "on or about" July 9.Banksread more
GE hasn't had a year this good during this millennium. After that massive surge, one trader is warning investors to stay away.Trading Nationread more
Johnson & Johnson's profit jumped 42% in the second quarter, with all three of the sprawling health-care company's businesses performing better than Wall Street expected.Health and Scienceread more
President Donald Trump and the RNC are picking up key supporters in the business community who did not back him as a candidate in 2016.2020 Electionsread more
Goldman Sachs reported second-quarter results that beat analysts' expectations Tuesday.Financeread more
Early Facebook investor and Trump supporter Peter Thiel weighed in on the Democrats taking on the president in 2020, saying he was "most scared' by Elizabeth Warren.2020 Electionsread more
Tensions between Japan and South Korea come as the U.S. and its trading partners are embroiled in a global trade war.Technologyread more
Shares of Seres Therapeutics plummeted more than 69 percent Friday after its microbiome treatment for preventing a bacterial infection failed in a mid-stage study and raised doubts about this growing area of research.
The product, known as SER-109, is a mix of bacterial spores designed to treat patients from recurring infection of the potentially deadly bacterium Clostridium difficile, or C. diff.
In a phase 2 study, SER-109 did not reduce the risks associated with the infection, compared to the placebo, at up to eight weeks of treatment.
Seres Chairman and CEO Roger Pomerantz said, in a press release, that the clinical results were "unexpected" in view of positive data in prior investigations and supporting clinical data.
"Specifically, the recurrence rates observed in the overall SER-109 treatment group, in the age stratified subgroups, and in the placebo groups are inconsistent with our expectations," he said. "Our priority is to complete a full review of the clinical results and microbiome data of the phase 2 study and to compare it to data from the prior investigator sponsored Phase 1b."
Seres said it will continue to gather and analyze study data, and in consultation with the U.S. Food and Drug Administration, make appropriate adjustments to its SER-109 development plans.
However, investors saw the results as potentially warning about the entire area of microbiome therapeutics, which has been looked on with much promise. The burgeoning field looks to treat illnesses by adding "good" bacteria to your digestive tract.
Seres is one of several companies racing to do that. Others include Vedanta Biosciences, Enterome, Second Genome and uBiome.
The spokesman for Seres didn't immediately respond for CNBC's request for comment.
MCRB 2016 Stock
Correction: An earlier version mischaracterized EpiBiome's approach to microbiome therapeutics.